https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-09-21 / Int J Hyperthermia 2010;26(8):748-64
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-09-21 / Int J Hyperthermia 2010;26(8):748-642010-09-21 00:00:002019-02-15 10:00:35Measurement and mathematical modeling of thermally induced injury and heat shock protein expression kinetics in normal and cancerous prostate cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-09-21 / Int J Hyperthermia 2011;27(2):180-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-09-21 / Int J Hyperthermia 2011;27(2):180-62010-09-21 00:00:002019-02-15 09:17:26Intracavity hyperthermia in nasopharyngeal cancer: a phase III clinical study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-09-21 / Mol. Cancer Ther. 2010 Oct;9(10):2761-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-09-21 / Mol. Cancer Ther. 2010 Oct;9(10):2761-92010-09-21 00:00:002010-09-21 00:00:00Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-09-07 / Cancer Res. 2010 Sep;70(18):7093-101
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-09-07 / Cancer Res. 2010 Sep;70(18):7093-1012010-09-07 00:00:002019-02-15 08:40:15IFN{gamma} markedly cooperates with intratumoral dendritic cell vaccine in dog tumor models
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-09-01 / Dan Med Bull 2010 Sep;57(9):B4171
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-09-01 / Dan Med Bull 2010 Sep;57(9):B41712010-09-01 00:00:002019-02-15 08:46:06Dendritic cell vaccination of patients with metastatic colorectal cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-09-01 / PLoS ONE 2010 Sep;5(9)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-09-01 / PLoS ONE 2010 Sep;5(9)2010-09-01 00:00:002019-02-15 08:52:57Harnessing naturally occurring tumor immunity: a clinical vaccine trial in prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-09-01 / Anticancer Res 2010 Sep;30(9):3709-14
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-09-01 / Anticancer Res 2010 Sep;30(9):3709-142010-09-01 00:00:002024-03-18 10:58:36Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-08-24 / Clin. Cancer Res. 2010 Oct;16(20):5067-78
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-08-24 / Clin. Cancer Res. 2010 Oct;16(20):5067-782010-08-24 00:00:002019-02-15 08:49:24Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-08-22 / Cancer Biol. Ther. 2010 Aug;10(4):368-75
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-08-22 / Cancer Biol. Ther. 2010 Aug;10(4):368-752010-08-22 00:00:002020-01-08 10:10:16Dendritic cells-mediated CTLs targeting hepatocellular carcinoma stem cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-08-13 / Vaccine 2010 Oct;28(42):6891-900
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-08-13 / Vaccine 2010 Oct;28(42):6891-9002010-08-13 00:00:002021-11-15 17:00:34The hemagglutinin-neuraminidase gene of Newcastle Disease Virus: a powerful molecular adjuvant for DNA anti-tumor vaccination
